Join DiaMedica Therapeutics for a virtual key opinion leader (KOL) event featuring Prof. Catherine Cluver, MD, PhD (Stellenbosch University), Prof. Stephen Tong, MD, PhD (The University of Melbourne), and Prof. Susan Walker, MD, PhD (The University of Melbourne) who will discuss the unmet need and current treatment landscape for preeclampsia (PE), a life-threatening pregnancy associated vascular disorder with no approved therapeutics. These doctors have an established history together including the creation of the only research collaboration in the world running successive clinical trials of drugs to treat preeclampsia. Their research unit has possibly recruited more women into preeclampsia treatment trials than all other clinical trials published by others, combined.

This will be followed by a discussion on the uniquely on-target mechanism of action of DM199 (rinvecalinase alfa) and its potential as a treatment for PE, and the upcoming Phase 2, proof-of-concept clinical trial of DM199 in PE.

The event will focus on DiaMedica’s expansion of its DM199 (recombinant human tissue kallikrein-1 (rhKLK1)) clinical development program and provide an overview of the Phase 2 investigator-sponsored trial in PE and fetal growth restriction, a separate yet related pregnancy disorder that is more prevalent and, like PE, currently has no FDA-approved therapeutics. DM199, through restoration of the body’s natural ability to produce nitric oxide, prostacyclin and endothelium-derived hyper polarizing factor, has the potential to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.

A live question & answer session will follow the formal presentations.